| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) EA Eisenhauer, P Therasse, J Bogaerts, LH Schwartz, D Sargent, R Ford, ... European journal of cancer 45 (2), 228-247, 2009 | 25615 | 2009 |
| Prospective randomized trial of docetaxel versus best supportive care in patients with non–small-cell lung cancer previously treated with platinum-based chemotherapy FA Shepherd, J Dancey, R Ramlau, K Mattson, R Gralla, M O’Rourke, ... Journal of Clinical Oncology 41 (15), 2673-2681, 2023 | 2809 | 2023 |
| A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer RC Coombes, E Hall, LJ Gibson, R Paridaens, J Jassem, T Delozier, ... New England Journal of Medicine 350 (11), 1081-1092, 2004 | 2331 | 2004 |
| iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics L Seymour, J Bogaerts, A Perrone, R Ford, LH Schwartz, S Mandrekar, ... The Lancet Oncology 18 (3), e143-e152, 2017 | 1688 | 2017 |
| RECIST 1.1—Update and clarification: From the RECIST committee LH Schwartz, S Litière, E De Vries, R Ford, S Gwyther, S Mandrekar, ... European journal of cancer 62, 132-137, 2016 | 1234 | 2016 |
| Phase II trial of gefitinib in recurrent glioblastoma JN Rich, DA Reardon, T Peery, JM Dowell, JA Quinn, KL Penne, ... Journal of Clinical Oncology 22 (1), 133-142, 2004 | 844 | 2004 |
| Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study E Galanis, JC Buckner, MJ Maurer, JI Kreisberg, K Ballman, J Boni, ... Journal of Clinical Oncology 23 (23), 5294-5304, 2005 | 812 | 2005 |
| Issues and progress with protein kinase inhibitors for cancer treatment J Dancey, EA Sausville Nature reviews Drug discovery 2 (4), 296-313, 2003 | 789 | 2003 |
| Response assessment criteria for brain metastases: proposal from the RANO group NU Lin, EQ Lee, H Aoyama, IJ Barani, DP Barboriak, BG Baumert, ... The lancet oncology 16 (6), e270-e278, 2015 | 716 | 2015 |
| Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme SM Chang, P Wen, T Cloughesy, H Greenberg, D Schiff, C Conrad, K Fink, ... Investigational new drugs 23, 357-361, 2005 | 459 | 2005 |
| Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of … MJ Moore, J Hamm, J Dancey, PD Eisenberg, M Dagenais, A Fields, ... Journal of clinical oncology 21 (17), 3296-3302, 2003 | 456 | 2003 |
| mTOR signaling and drug development in cancer J Dancey Nature reviews Clinical oncology 7 (4), 209-219, 2010 | 427 | 2010 |
| Strategies for optimizing combinations of molecularly targeted anticancer agents JE Dancey, HX Chen Nature reviews Drug discovery 5 (8), 649-659, 2006 | 419 | 2006 |
| Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma MB Thomas, R Chadha, K Glover, X Wang, J Morris, T Brown, A Rashid, ... Cancer 110 (5), 1059-1067, 2007 | 410 | 2007 |
| Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer KS Saini, S Loi, E de Azambuja, O Metzger-Filho, ML Saini, M Ignatiadis, ... Cancer treatment reviews 39 (8), 935-946, 2013 | 391 | 2013 |
| The genetic basis for cancer treatment decisions JE Dancey, PL Bedard, N Onetto, TJ Hudson Cell 148 (3), 409-420, 2012 | 384 | 2012 |
| Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group AM Oza, L Elit, MS Tsao, S Kamel-Reid, J Biagi, DM Provencher, ... Journal of Clinical Oncology 29 (24), 3278, 2011 | 376 | 2011 |
| A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas I Duran, J Kortmansky, D Singh, H Hirte, W Kocha, G Goss, L Le, A Oza, ... British journal of cancer 95 (9), 1148-1154, 2006 | 372 | 2006 |
| Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres JE Dancey, FA Shepherd, K Paul, KW Sniderman, S Houle, J Gabrys, ... Journal of nuclear medicine 41 (10), 1673-1681, 2000 | 357 | 2000 |
| A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer RK Ramanathan, CP Belani, DA Singh, M Tanaka, HJ Lenz, Y Yen, ... Cancer chemotherapy and pharmacology 64, 777-783, 2009 | 327 | 2009 |
